Other names：Linzess 851199-59-2 UNII-N0TXR0XR5X Linaclotide
Raw Linaclotide powder(851199-59-2) , sold under the brand name Linzess in the US and Mexico, and as Constella elsewhere, is an oral drug used to treat irritable bowel syndrome accompanied by constipation and unexplained chronic constipation.
◐ Production capacity: Provide customization
◐ Large Factory Professional Manufacturers & Factory
◐ Production Carried OUT Under CGMP Regulation and Trackable
◐ ISO9001 & ISO14000
Get a Bulk quotation
If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.
Coa & MS
Where to buy?
Coa & MS
Where to buy?
Linaclotide Peptide dosage calculator
1.Johnston JM, Shiff SJ, Quigley EM. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Curr Med Res Opin. 2013 Feb;29(2):149-60. [PubMed]
2.Pohl D, Fried M, Lawrance D, Beck E, Hammer HF. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study. BMJ Open. 2019 Dec 30;9(12):e025627. [PMC free article] [PubMed]
3.Andresen V, Miehlke S, Beck E, Wiseman G, Layer P. Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a realworld setting – results from a German noninterventional study. Z Gastroenterol. 2018 Jul;56(7):738-744. [PubMed]
4.Vazquez Roque M, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):301-10. [PubMed]
5.Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. [PubMed]
7.Brenner DM, Argoff CE, Fox SM, Bochenek W, D’Astoli P, Blakesley RE, Reasner DS, O’Dea CR, Cash BD. Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. Pain. 2020 May;161(5):1027-1036. [PMC free article] [PubMed]
8.Folgueira C, Torres-Leal FL, Beiroa D, Pena-León V, Da Silva Lima N, Milbank E, Senra A, Al-Massadi O, López M, Diéguez C, Seoane LM, Nogueiras R. Oral Pharmacological Activation of Hypothalamic Guanylate Cyclase 2C Receptor Stimulates Brown Fat Thermogenesis to Reduce Body Weight. Neuroendocrinology. 2020;110(11-12):1042-1054. [PubMed]
9.McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, Hao S, Jafri A, Drumm ML, Boron WF, Stern RC, McBennett K, Hodges CA. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol. 2018 Nov 01;315(5):G868-G878. [PMC free article] [PubMed]
11.Nanto-Hara F, Kanemitsu Y, Fukuda S, Kikuchi K, Asaji K, Saigusa D, Iwasaki T, Ho HJ, Mishima E, Suzuki T, Suzuki C, Tsukimi T, Matsuhashi T, Oikawa Y, Akiyama Y, Kure S, Owada Y, Tomioka Y, Soga T, Ito S, Abe T. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dial Transplant. 2020 Feb 01;35(2):250-264. [PubMed]
12.Brierley SM. Guanylate cyclase-C receptor activation: unexpected biology. Curr Opin Pharmacol. 2012 Dec;12(6):632-40. [PubMed]
13.Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010 May 08;86(19-20):760-5. [PubMed]
14.Bassotti G, Usai-Satta P, Bellini M. Linaclotide for the treatment of chronic constipation. Expert Opin Pharmacother. 2018 Aug;19(11):1261-1266. [PubMed]
15.McCormack PL. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation. Drugs. 2014 Jan;74(1):53-60. [PubMed]
Author of this article:
Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine.
Scientific Journal paper Author:
Corresponding author. Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Corresponding author at: Department of Pharmacology, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, Egypt.
Reprint requests: Xiaobin Sun, MB, Department of Gastroenterology, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610000, Sichuan, China.
Reprint requests Address requests for reprints to: Stuart M. Brierley, PhD, Nerve-Gut Research Laboratory, Level 1 Hanson Institute, Frome Road, Adelaide, South Australia
In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.